InnoSIGN utilizes OncoSIGNal pathway activity profiling technology to quantify cell signaling pathways in cancer, enhancing the understanding of disease mechanisms. This approach enables the translation of molecular data into functional cell behavior, improving personalized treatment strategies for cancer patients.
Funding
$22.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Despite the increasing availability of multi-omics data in cancer research, treatment decisions often rely on analyzing single-point mutations, which provides an incomplete picture of the disease's underlying mechanisms. This approach can lead to suboptimal treatment strategies and limit the potential for durable patient outcomes.
Solution
InnoSIGN offers a comprehensive disease analysis platform that transforms complex multi-omics data into actionable insights, enabling a deeper understanding of the cell signaling pathways driving cancer. The platform utilizes a proprietary algorithm to identify key drivers of disease, facilitating improved treatment selection and accelerated drug discovery. By quantifying cell signaling pathways, InnoSIGN's OncoSIGNal technology translates molecular data into functional cell behavior, providing clinicians and researchers with a more complete understanding of disease mechanisms. The platform's locked design is applicable across various diseases and supports the full drug development continuum, from preclinical studies to companion diagnostics and commercial launch.
Target Audience
InnoSIGN's primary customers include pharmaceutical companies, clinical researchers, and healthcare providers focused on oncology and precision medicine.
Features
- Proprietary algorithm transforms multi-omics data into actionable insights
- OncoSIGNal technology quantifies cell signaling pathways to reveal functional cell behavior
- Identifies key drivers of disease to improve treatment selection
- Supports the full drug development continuum, from preclinical to CDx to commercial launch
- Applicable across a range of diseases